炎症性肠病的特征和治疗的时间趋势。

IF 1.6 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY
Jessica C Young, Lise M Helsingen, Erle Refsum, Amanda Högdén, Vera Perrin, Magnus Løberg, Rasmus H Gantzel, Michael Bretthauer, Anita Berglund, Øyvind Holme, Henriette Cecilie Jodal, Tore Grimstad, Stephan A Brackmann, Weimin Ye, Hans-Olov Adami, Lone Larsen, Miguel A Hernan, Tine Jess, Johannes Blom, Mette Kalager
{"title":"炎症性肠病的特征和治疗的时间趋势。","authors":"Jessica C Young, Lise M Helsingen, Erle Refsum, Amanda Högdén, Vera Perrin, Magnus Løberg, Rasmus H Gantzel, Michael Bretthauer, Anita Berglund, Øyvind Holme, Henriette Cecilie Jodal, Tore Grimstad, Stephan A Brackmann, Weimin Ye, Hans-Olov Adami, Lone Larsen, Miguel A Hernan, Tine Jess, Johannes Blom, Mette Kalager","doi":"10.1080/00365521.2025.2478166","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Inflammatory bowel disease (IBD) requires complex clinical management. Despite substantial advancements in endoscopy and in pharmacotherapies for patients with IBD, it remains unclear how these developments have influenced IBD incidence and clinical care. We aim to describe changes in diagnostic and therapeutic practices in IBD management.</p><p><strong>Methods: </strong>All individuals diagnosed with IBD between 1987 and 2016 were identified from nationwide registries in Norway and Sweden. We performed detailed chart abstractions for a random sample of the cohort. We describe patient characteristics, disease extent, endoscopic practices, pathology diagnostics, pharmacological therapy and surgical management, stratifying by Crohn's disease (CD) and ulcerative colitis [UC], comparing patients diagnosed before (pre-biologic period, 1987-1999), and after the introduction of biologic drugs (biologic period, 2000-2016).</p><p><strong>Results: </strong>Chart abstraction was completed for 791 individuals (UC: 58.8%, Crohn's disease: 40.2%, unclassified IBD: 1.0%). Comparing the biologic period to the pre-biologic period, we observed an increase in endoscopies after diagnosis, more frequent colonoscopies, and a decrease in colon resection rates. Among those diagnosed in 2007 or later compared with those diagnosed between 2000 and 2006, there was a higher treatment initiation rate of azathioprine, infliximab and adalimumab within 1 year after diagnosis.</p><p><strong>Conclusions: </strong>Our findings suggest a shift towards more frequent endoscopy, increased use of immunosuppressants and biologics, and decreased colon resection rates in recent periods.</p>","PeriodicalId":21461,"journal":{"name":"Scandinavian Journal of Gastroenterology","volume":" ","pages":"1-9"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Temporal trends in characteristics and management of inflammatory bowel disease.\",\"authors\":\"Jessica C Young, Lise M Helsingen, Erle Refsum, Amanda Högdén, Vera Perrin, Magnus Løberg, Rasmus H Gantzel, Michael Bretthauer, Anita Berglund, Øyvind Holme, Henriette Cecilie Jodal, Tore Grimstad, Stephan A Brackmann, Weimin Ye, Hans-Olov Adami, Lone Larsen, Miguel A Hernan, Tine Jess, Johannes Blom, Mette Kalager\",\"doi\":\"10.1080/00365521.2025.2478166\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Inflammatory bowel disease (IBD) requires complex clinical management. Despite substantial advancements in endoscopy and in pharmacotherapies for patients with IBD, it remains unclear how these developments have influenced IBD incidence and clinical care. We aim to describe changes in diagnostic and therapeutic practices in IBD management.</p><p><strong>Methods: </strong>All individuals diagnosed with IBD between 1987 and 2016 were identified from nationwide registries in Norway and Sweden. We performed detailed chart abstractions for a random sample of the cohort. We describe patient characteristics, disease extent, endoscopic practices, pathology diagnostics, pharmacological therapy and surgical management, stratifying by Crohn's disease (CD) and ulcerative colitis [UC], comparing patients diagnosed before (pre-biologic period, 1987-1999), and after the introduction of biologic drugs (biologic period, 2000-2016).</p><p><strong>Results: </strong>Chart abstraction was completed for 791 individuals (UC: 58.8%, Crohn's disease: 40.2%, unclassified IBD: 1.0%). Comparing the biologic period to the pre-biologic period, we observed an increase in endoscopies after diagnosis, more frequent colonoscopies, and a decrease in colon resection rates. Among those diagnosed in 2007 or later compared with those diagnosed between 2000 and 2006, there was a higher treatment initiation rate of azathioprine, infliximab and adalimumab within 1 year after diagnosis.</p><p><strong>Conclusions: </strong>Our findings suggest a shift towards more frequent endoscopy, increased use of immunosuppressants and biologics, and decreased colon resection rates in recent periods.</p>\",\"PeriodicalId\":21461,\"journal\":{\"name\":\"Scandinavian Journal of Gastroenterology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00365521.2025.2478166\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365521.2025.2478166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:炎症性肠病(IBD)需要复杂的临床治疗。尽管在IBD患者的内窥镜检查和药物治疗方面取得了实质性进展,但这些进展如何影响IBD的发病率和临床护理仍不清楚。我们的目的是描述在IBD管理诊断和治疗实践的变化。方法:1987年至2016年间,所有被诊断为IBD的个体均来自挪威和瑞典的全国登记中心。我们对队列中的随机样本进行了详细的图表抽象。我们描述了患者的特征、疾病程度、内镜操作、病理诊断、药物治疗和手术管理,并按克罗恩病(CD)和溃疡性结肠炎(UC)进行分层,比较了在引入生物药物前(1987-1999年)和引入生物药物后(2000-2016年)诊断的患者。结果:791例患者完成了图表提取(UC: 58.8%,克罗恩病:40.2%,未分类IBD: 1.0%)。与生物期前相比,我们观察到诊断后内窥镜检查次数增加,结肠镜检查次数增加,结肠切除率下降。在2007年及以后诊断的患者中,与2000 - 2006年诊断的患者相比,在诊断后1年内,硫唑嘌呤、英夫利昔单抗和阿达木单抗的治疗起始率更高。结论:我们的研究结果表明,在最近一段时间内,更频繁的内窥镜检查,免疫抑制剂和生物制剂的使用增加,结肠切除术率下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Temporal trends in characteristics and management of inflammatory bowel disease.

Background and aims: Inflammatory bowel disease (IBD) requires complex clinical management. Despite substantial advancements in endoscopy and in pharmacotherapies for patients with IBD, it remains unclear how these developments have influenced IBD incidence and clinical care. We aim to describe changes in diagnostic and therapeutic practices in IBD management.

Methods: All individuals diagnosed with IBD between 1987 and 2016 were identified from nationwide registries in Norway and Sweden. We performed detailed chart abstractions for a random sample of the cohort. We describe patient characteristics, disease extent, endoscopic practices, pathology diagnostics, pharmacological therapy and surgical management, stratifying by Crohn's disease (CD) and ulcerative colitis [UC], comparing patients diagnosed before (pre-biologic period, 1987-1999), and after the introduction of biologic drugs (biologic period, 2000-2016).

Results: Chart abstraction was completed for 791 individuals (UC: 58.8%, Crohn's disease: 40.2%, unclassified IBD: 1.0%). Comparing the biologic period to the pre-biologic period, we observed an increase in endoscopies after diagnosis, more frequent colonoscopies, and a decrease in colon resection rates. Among those diagnosed in 2007 or later compared with those diagnosed between 2000 and 2006, there was a higher treatment initiation rate of azathioprine, infliximab and adalimumab within 1 year after diagnosis.

Conclusions: Our findings suggest a shift towards more frequent endoscopy, increased use of immunosuppressants and biologics, and decreased colon resection rates in recent periods.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
5.30%
发文量
222
审稿时长
3-8 weeks
期刊介绍: The Scandinavian Journal of Gastroenterology is one of the most important journals for international medical research in gastroenterology and hepatology with international contributors, Editorial Board, and distribution
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信